Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma

Weiming Mao, Yang Liu, Robert J. Wordinger, Abbot Clark, Iok-Hou Pang

Research output: Contribution to journalReview article

Abstract

Glaucoma is a major cause of blindness in China and the world. Currently, all therapeutic means in treating open-angle glaucoma are limited to control the progression of optic neuropathy by lowering intraocular pressure (IOP). Clinically available medicines lower IOP by either enhancing the uveoscleral pathway or inhibiting aqueous humor production. Since the primary cause of IOP elevation in POAG is elevated outflow resistance in the trabecular outflow pathway, current medicines are not able to correct the underlying pathogenesis and pathophysiology of the disease. In this review article, we discuss a series of new therapeutic targets and therapeutic approaches that are designed to directly modify the pathological changes related to the reduction in trabecular outflow in glaucoma patients. Some of these targets and approaches may produce a significant breakthrough in the treatment of this devastating disease.

Original languageEnglish
Pages (from-to)471-475
Number of pages5
JournalChinese Journal of Ophthalmology
Volume52
Issue number6
DOIs
StatePublished - 11 Jun 2016

Fingerprint

Intraocular Pressure
Glaucoma
Optic Nerve Diseases
Aqueous Humor
Open Angle Glaucoma
Blindness
Therapeutics
China
Primary Open Angle Glaucoma

Keywords

  • Drug discovery
  • Glaucoma, open-angle
  • Molecular targeted therapy
  • Trabecular meshwork

Cite this

@article{1b93b9a5646f46f2b1b89ee518f284c8,
title = "Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma",
abstract = "Glaucoma is a major cause of blindness in China and the world. Currently, all therapeutic means in treating open-angle glaucoma are limited to control the progression of optic neuropathy by lowering intraocular pressure (IOP). Clinically available medicines lower IOP by either enhancing the uveoscleral pathway or inhibiting aqueous humor production. Since the primary cause of IOP elevation in POAG is elevated outflow resistance in the trabecular outflow pathway, current medicines are not able to correct the underlying pathogenesis and pathophysiology of the disease. In this review article, we discuss a series of new therapeutic targets and therapeutic approaches that are designed to directly modify the pathological changes related to the reduction in trabecular outflow in glaucoma patients. Some of these targets and approaches may produce a significant breakthrough in the treatment of this devastating disease.",
keywords = "Drug discovery, Glaucoma, open-angle, Molecular targeted therapy, Trabecular meshwork",
author = "Weiming Mao and Yang Liu and Wordinger, {Robert J.} and Abbot Clark and Iok-Hou Pang",
year = "2016",
month = "6",
day = "11",
doi = "10.3760/cma.j.issn.0412-4081.2016.06.019",
language = "English",
volume = "52",
pages = "471--475",
journal = "Chinese Journal of Ophthalmology",
issn = "0412-4081",
publisher = "Chinese Medical Association",
number = "6",

}

Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma. / Mao, Weiming; Liu, Yang; Wordinger, Robert J.; Clark, Abbot; Pang, Iok-Hou.

In: Chinese Journal of Ophthalmology, Vol. 52, No. 6, 11.06.2016, p. 471-475.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma

AU - Mao, Weiming

AU - Liu, Yang

AU - Wordinger, Robert J.

AU - Clark, Abbot

AU - Pang, Iok-Hou

PY - 2016/6/11

Y1 - 2016/6/11

N2 - Glaucoma is a major cause of blindness in China and the world. Currently, all therapeutic means in treating open-angle glaucoma are limited to control the progression of optic neuropathy by lowering intraocular pressure (IOP). Clinically available medicines lower IOP by either enhancing the uveoscleral pathway or inhibiting aqueous humor production. Since the primary cause of IOP elevation in POAG is elevated outflow resistance in the trabecular outflow pathway, current medicines are not able to correct the underlying pathogenesis and pathophysiology of the disease. In this review article, we discuss a series of new therapeutic targets and therapeutic approaches that are designed to directly modify the pathological changes related to the reduction in trabecular outflow in glaucoma patients. Some of these targets and approaches may produce a significant breakthrough in the treatment of this devastating disease.

AB - Glaucoma is a major cause of blindness in China and the world. Currently, all therapeutic means in treating open-angle glaucoma are limited to control the progression of optic neuropathy by lowering intraocular pressure (IOP). Clinically available medicines lower IOP by either enhancing the uveoscleral pathway or inhibiting aqueous humor production. Since the primary cause of IOP elevation in POAG is elevated outflow resistance in the trabecular outflow pathway, current medicines are not able to correct the underlying pathogenesis and pathophysiology of the disease. In this review article, we discuss a series of new therapeutic targets and therapeutic approaches that are designed to directly modify the pathological changes related to the reduction in trabecular outflow in glaucoma patients. Some of these targets and approaches may produce a significant breakthrough in the treatment of this devastating disease.

KW - Drug discovery

KW - Glaucoma, open-angle

KW - Molecular targeted therapy

KW - Trabecular meshwork

UR - http://www.scopus.com/inward/record.url?scp=84986212683&partnerID=8YFLogxK

U2 - 10.3760/cma.j.issn.0412-4081.2016.06.019

DO - 10.3760/cma.j.issn.0412-4081.2016.06.019

M3 - Review article

C2 - 27373575

AN - SCOPUS:84986212683

VL - 52

SP - 471

EP - 475

JO - Chinese Journal of Ophthalmology

JF - Chinese Journal of Ophthalmology

SN - 0412-4081

IS - 6

ER -